Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Sells $1,005,200.00 in Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Lantheus Trading Down 1.2 %

Shares of NASDAQ:LNTH opened at $97.71 on Friday. The firm’s 50 day moving average is $92.67 and its two-hundred day moving average is $96.64. Lantheus Holdings, Inc. has a 52 week low of $57.92 and a 52 week high of $126.89. The firm has a market capitalization of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on LNTH. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Finally, B. Riley dropped their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Institutional Investors Weigh In On Lantheus

Several large investors have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the fourth quarter valued at approximately $27,000. Summit Securities Group LLC bought a new position in shares of Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. boosted its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC bought a new position in shares of Lantheus in the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.